These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8486957)

  • 61. The duration of the antibody response to meningococcal vaccination in an African village.
    Greenwood BM; Whittle HC; Bradley AK; Fayet MT; Gilles HM
    Trans R Soc Trop Med Hyg; 1980; 74(6):756-60. PubMed ID: 6782720
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
    Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy.
    McCormick JB; Gusmão HH; Nakamura S; Freire JB; Veras J; Gorman G; Feeley JC; Wingo P
    J Clin Invest; 1980 May; 65(5):1141-4. PubMed ID: 6767739
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.
    Bårnes GK; Workalemahu B; Kristiansen PA; Beyene D; Merdekios B; Fissiha P; Aseffa A; Caugant DA; Naess LM
    Scand J Immunol; 2016 Aug; 84(2):118-29. PubMed ID: 27219622
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.
    Herva E; Leinonen M; Käyhty H; Mäkelä PH; Vetoniemi-Korhonen SL
    J Infect; 1983 Jan; 6(1):55-60. PubMed ID: 6411822
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Serological evaluation of polyvalent A-C anti-meningococcal vaccine in Chile].
    García Moreno J; Prat Miranda MS; Vicent P; Calderón B
    Bol Oficina Sanit Panam; 1982 Aug; 93(2):149-57. PubMed ID: 6215047
    [No Abstract]   [Full Text] [Related]  

  • 69. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
    Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
    Pearce MC; Sheridan JW; Jones DM; Lawrence GW; Murphy DM; Masutti B; McCosker C; Douglas V; George D; O'Keefe A
    Lancet; 1995 Jul; 346(8966):20-3. PubMed ID: 7603139
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.
    Borrow R; Richmond P; Kaczmarski EB; Iverson A; Martin SL; Findlow J; Acuna M; Longworth E; O'Connor R; Paul J; Miller E
    FEMS Immunol Med Microbiol; 2000 May; 28(1):79-85. PubMed ID: 10767611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
    Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA
    Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The epidemiological impact of antimeningococcal B vaccination in Cuba.
    Rodriguez AP; Dickinson F; Baly A; Martinez R
    Mem Inst Oswaldo Cruz; 1999; 94(4):433-40. PubMed ID: 10445998
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness of BC meningococcal vaccine in Brazil.
    Nishioka S
    Int J Epidemiol; 1996 Oct; 25(5):1102-3. PubMed ID: 8921501
    [No Abstract]   [Full Text] [Related]  

  • 76. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.
    MacLennan J; Obaro S; Deeks J; Williams D; Pais L; Carlone G; Moxon R; Greenwood B
    Vaccine; 1999 Aug; 17(23-24):3086-93. PubMed ID: 10462244
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The antibody response of animals to a corpuscular meningococcal group-B preparation with different methods of immunization].
    Aleksakhina NN; Basnak'ian IA; Kolenko VM; Borovkova VM; Saraeva LV; Stukalova NV; Karabak VI
    Zh Mikrobiol Epidemiol Immunobiol; 1992; (7-8):30-4. PubMed ID: 1466168
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein.
    Thiesen B; Greenwood B; Brieske N; Achtman M
    Vaccine; 1997 Feb; 15(2):209-19. PubMed ID: 9066040
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Group C Neisseria meningitidis variant polysaccharide vaccines in children.
    Steinhoff MC; Lewin EB; Gotschlich EC; Robbins JB
    Infect Immun; 1981 Oct; 34(1):144-6. PubMed ID: 6795122
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.
    Platonov AE; Beloborodov VB; Pavlova LI; Vershinina IV; Käyhty H
    Clin Exp Immunol; 1995 Apr; 100(1):32-9. PubMed ID: 7697919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.